Suzhou, China – Peijia Medical Technology has signed a strategic innovation partnership with Dutch-headquartered DSM-Firmenich to create new polymeric materials for artificial heart valves. Peijia said this is “expected to initiate an epoch-making transformation in the field of high-end medical device materials worldwide”.
The focus is on TPU and ultra-high MW PE from DSM-Firmenich’s biomedical business. The R&D teams will collaborate on the design and development of new high-end medical device products, the R&D of new materials, and the optimisation of key raw material properties.
Peijia specialises in medical devices for structural heart disease and cerebrovascular intervention. Its product development team is working on products to treat valvular diseases, as well as next-generation technologies. The company has numerous products on the market, including coils to treat brain aneurysms and devices for ischaemic stroke.
